NDA/PLA REVIEWS MAY NOT BE DELAYED DUE TO GENERAL DATA INTEGRITY ISSUES UNDER PhRMA FDA REFORM PLAN; OTC OFFICE WOULD RETURN TO REVIEW ALL SWITCHES
Executive Summary
FDA's "applications integrity policy" would be overturned by a provision of the Pharmaceutical Research & Manufacturers of America FDA reform plan.
You may also be interested in...
Clarinex Approval Precedes Consent Decree, But Follows Schering GMP Work
The approval of Schering-Plough's antihistamine Clarinex reflects the company's re-qualification and re-validation of equipment in its Las Piedras, Puerto Rico manufacturing facility
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011